Clinical Trial Update: Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts [Phase 1]

View source ↗

Summary

Phase 1 study evaluating talazoparib for cohesin-mutated acute myeloid leukemia and myelodysplastic syndrome with excess blasts; the trial is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts

Drugs mentioned

• Talzenna (talazoparib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING